Top stories in hematology/oncology: High fiber consumption may lower breast cancer risk, watch-and-wait strategy in rectal cancer
Click Here to Manage Email Alerts
High consumption of fiber was linked to a reduced risk for break cancer, according to results of a meta-analysis published in Cancer. It was the top story in hematology/oncology last week.
Another top story was about the potential benefit of a nonoperative watch-and-wait strategy for some patients with rectal cancer.
Read these and more top stories in hematology/oncology below:
Fiber consumption linked to lower breast cancer risk
High fiber consumption appeared to be associated with reduced risk for breast cancer, according to results of a meta-analysis of prospective observational studies published in Cancer. Read more.
Watch-and-wait strategy may be appropriate for certain patients with rectal cancer
A nonoperative watch-and-wait strategy appeared comparable to upfront surgery in survival outcomes and could confer a quality-of-life benefit and significant cost savings for certain patients with rectal cancer, according to results of a modeling study published in Journal of the National Cancer Institute. Read more.
FDA grants priority review to Keytruda for patients with high tumor mutational burden
The FDA granted priority review to pembrolizumab (Keytruda; Merck) for the treatment of adults and children with unresectable or metastatic solid tumors who have high tissue tumor mutational burden. Read more.
Stereotactic ablative radiotherapy confers clinical benefit in oligometastatic prostate cancer
Stereotactic ablative radiotherapy appeared to improve clinical outcomes compared with observation among men with oligometastatic prostate cancer, according to results of the randomized phase 2 ORIOLE study published in JAMA Oncology. Read more.
FDA approves Braftovi with Erbitux for metastatic colorectal cancer subset
The FDA approved encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, Eli Lilly) for adults with previously treated BRAF V600E-mutant metastatic colorectal cancer. Read more.